Statins Act As a Shield Against Diabetic Macular Edema
AUGUST 11, 2016
Previous studies have shown that fenofibrate, approved in 2008 to be used with a statin, is beneficial for diabetic retinopathy (DR). However, it’s unknown how it impacts the progression DR or how it influences diabetic macular edema (DME). Park and team discussed their findings in a poster presentation at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.
The researchers reviewed the medical records from 110 patients with DR and type 2 diabetes. Early Treatment Diabetic Retinopathy Study (ETDRS) methods measured the DR severity scale (DRSS) outcomes and optical coherence tomography (OCT) confirmed any DME diagnoses.
DME was diagnosed in 23% of the patients with statins and 48% of those without. There were no significant differences in DRSS outcomes between the groups.
“Higher triglycerides level was significantly associate with central retinal thickness severity risk in DME patients,” the team confirmed.
The use of statins did not impact the progression of DR, however, the drugs showed to be a protective agent against DME prevalence.
Hypertriglyceridemia should be closely monitored, the researchers advised. Add-on therapies such as fenofibrate, niacin, and fish oil could help prevent the incidence of DME in people with DR and type 2 diabetes.
Also on MD Magazine >>> More News from ASRS 2016 in San Francisco